Gränslös Innovation Cristina Glad Skånska Utvecklingsdagen 14 november 2005 Presentationen har inför publicering på skane.se rensats på bildelement pga utrymmesskäl.
14 samverkande Universitet 26 sjukhus varav 11 universitetssjukhus
Acumulated total of new biotech companies (excluding medical technology and CROs) Total no of start-ups: 110 Still existing 2005: 95 Companies closed: 10 Mergers/Acquisitions: 5
Medicon Valley Blockbusters Cipramil (antidepressive) Lundbeck NovoPen (insulin) Novo Nordisk Turbuhaler (powder inhalator) AstraZeneca, Lund
Red=pharma; Pink= CRO; Yellow=medtech; Blue=biotech foods Violet=pharma production (only); Brown=biotech/bioproduction
Source: Critical I Limited The European biotech landscape
Bioteknikbolagen I Europa är många men har svårt att växa Source: Critical I Limited ”At the point at which Europe’s companies ought to be taking off, most of them appear to run out of financial runway”
Getting venture investment in European biotechnology depends on being in the right place Source: Critical I Limited
Capital to Biotech (Nov 2004-July 2005) BioEtt (Nov-04)0.6 Celltrix (Nov-04)1 Symphogen (Nov-04)21 Probi (IPO) (Dec-04)4 CMC (Jan-05)14 Ultrazonix (Jan-05)3 Zealand Pharma (Feb-05)26 LiPlasome (Mar-05) 6 SpectraCure (Mar-05)2 TopoTarget (Mar-05)15 Evolva (Mar-05)14 Mitra Medical (Mar-05)3 Acadia (Apr-05) 30 NsGene (May-05) 4 LifeCyclePharma (May-05)15 Exiqon (May-05)17 Pharmexa (publ.) (Jun-05)40 ProstaLund (Jun-05)3 TopoTarget (IPO) (Jul-05)31 Medtentia (Jul-05) 1 Active Biotech (Jul-05)18 TOTAL 60 >200 M€
Medicon Valley Academy Initiative 1995 from universities and big pharma companies 2000: Private membership based non profit organisation Universities, hospitals & companies (260 members) 2 nations – 2 systems
Innovation Potential in Medicon Valley Research Technology Transfer Companies From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report 300 million € university research 3200 publications/yr >150 inventions/yr 400 bio-companies 40,000 employees
1)More commercial know-how into Technology Transfer Organisations 2) Regional TTO cooperation (!) 3) Funding for Proof - of- Concept studies 4) Seed investments across Øresund (!) 5) Tax incentives for the Young Biotech Industry From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report Innovation Report 2004 Recommendations to improve the competitiveness of Medicon Valley
Våra Svagheter Svårt att växa Brist på kapital Kompetens inom utveckling och kommersialisering Svårt attrahera utländsk arbetskraft Skatter och avgifter Hjälpande infrastruktur
Vi måste vara attraktiva
Våra Styrkor Tillgång på högutbildad personal Tillgång på kompetens från andra företag Samarbete med akademin Innovationsklimatet inom akademin –Lärarundantaget –Holdingbolag, Innovationsbron etc.
BMC (Lund) Bio Medical Center CRC (Malmö) Clinical Research Center BRIC (Copenhagen) Biotech Research and Innovation Center Total investments billion € SWEGENE (Lund) Postgenomic RT Programme in South Western Sweden Research infrastructure investments
Proteomics Microarray Cryo-EM Genomic Ecology University Hospital BMC Ideon Science Park MAX-lab Transgenic core facility Bioinformatics Chemical Centre LTH Sony Ericsson Gambro Active Biotech Astra Zeneca 500 m School of Economics LUND North Campus Area ESS?